Pharmaceutical compositions for combination therapy
This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.
1. A method of reducing food intake by a human comprising:
administering to the human, 0.1 mg to 1 mg of Tesofensine, or a pharmaceutically acceptable salt thereof, daily
in combination with 0.25 mg to 200 mg of Metoprolol, or a pharmaceutically acceptable salt thereof, daily
wherein the combination is effective in reducing the food intake by the human and wherein the combination is effective in preventing or alleviating drug-induced cardiovascular side-effects.
2. The method of claim 1 , wherein 0.1 mg to about 0.5 mg of the Tesofensine is administered daily.
3. The method of claim 1 , wherein 25 mg to 100 mg of the Metoprolol is administered daily.
4. The method of claim 1 , wherein the human is a pre-obese human, an obese human, or a morbid obese human.
5. The method of claim 1 , wherein the human suffers from a condition selected from the group consisting of over-eating disorders, bulimia nervosa, binge eating disorder, compulsive over-eating, impaired appetite regulation, metabolic syndrome, type 2 diabetes, dyslipidemia, atherosclerosis, and drug-induced obesity.
6. The method of claim 1 , wherein the human suffers from type 2 diabetes.
7. A method of reducing body weight of a human comprising:
administering to the human 0.1 mg to 1 mg of Tesofensine, or a pharmaceutically acceptable salt thereof, daily,
in combination with 0.25 mg to 200 mg of Metoprolol, or a pharmaceutically acceptable salt thereof, daily;
wherein the combination is effective to reduce the body weight of the human and wherein the combination is effective in preventing or alleviating drug-induced cardiovascular side-effects.
8. The method of claim 7 , wherein 0.1 mg to about 0.5 mg of the Tesofensine is administered daily.
9. The method of claim 7 , wherein 25 mg to 100 mg of the Metoprolol is administered daily.
10. The method of claim 7 , wherein the obese human is a pre-obese human, an obese human, or a morbid obese human.
11. The method of claim 7 , wherein the human suffers from a condition selected from the group consisting of over-eating disorders, bulimia nervosa, binge eating disorder, compulsive over-eating, impaired appetite regulation, metabolic syndrome, type 2 diabetes, dyslipidemia, atherosclerosis, and drug-induced obesity.
12. The method of claim 7 , wherein the human suffers from type 2 diabetes.
13. The method of claim 1 , wherein the drug-induced cardiovascular side effects are increased heart rate, increased diastolic blood pressure, or increased systolic blood pressure, or a combination thereof.
14. The method of claim 7 , wherein the drug-induced cardiovascular side effects are increased heart rate, increased diastolic blood pressure, or increased systolic blood pressure, or a combination thereof.